Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

A global biopharmaceutical company has announced it will invest $1.5 billion for a new manufacturing facility in Bradley, but the taxpayer cost of the project is ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5-billion project.  | On Monday, CSL broke ground on an ...

CSL, a global pharmaceutical manufacturer based in Melbourne, Australia, has broken ground on a $1.5 billion expansion of its campus in Kankakee, roughly 60 miles southwest of Chicago. The company has ...

The Melbourne-based company will build a 330,000-square-foot facility and retain 1,200 existing positions. Construction is ...

The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more than $3 billion, and will focus on producing plasma-derived therapies.

KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that ...

We cut our fair value estimate for narrow-moat CSL by 22% to $210 due to our plasma earnings downgrades. However, shares are undervalued. Despite fiercer competition, we think we are more optimistic ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

CSL Behring has made a name for itself manufacturing biologics and plasma, but its unveiling of a new R&D site—slated to be the company’s largest—is evidence of expanded development efforts. The new ...